MASS · 908 Devices Inc.
Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Upcoming events
| Date | Event | Type |
|---|---|---|
| 2026-08-26 14:55 UTC | 17th Annual Midwest IDEAS Investor Conference | Conference |
Recent news
| Date | Headline |
|---|---|
| 2026-08-12 | 908 Devices to Present at the 17th Annual Midwest IDEAS Investor Conference |
| 2026-08-11 | 908 Devices Reports Second Quarter 2026 Financial Results and Raises Low End of 2026 Revenue Outlook |
| 2026-07-29 | 908 Devices to Participate in the Canaccord Genuity 46th Annual Growth Conference |
| 2026-07-28 | 908 Devices to Report Second Quarter 2026 Financial Results on August 11, 2026 |
| 2026-06-02 | 908 Devices Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
| 2026-05-28 | 908 Devices to Present at the 16th Annual East Coast IDEAS Investor Conference |
| 2026-05-06 | 908 Devices Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Outlook |
| 2026-05-06 | 908 Devices Acquires NIRLAB AG, Expanding Its Narcotics Detection Portfolio |
| 2026-05-01 | 908 Devices to Report First Quarter 2026 Financial Results on May 6, 2026 |
| 2026-04-21 | 908 Devices Appoints Kola Otitoju as Chief Business & Strategy Officer and Announces an Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-03-16 | 908 Devices to Present at the Sidoti Small Cap Conference |
| 2026-03-03 | 908 Devices Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Revenue Outlook |
| 2026-02-24 | 908 Devices to Participate in Investor Conferences in March |
| 2026-02-17 | 908 Devices to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026 |
| 2026-02-05 |
908 Devices Enhances MX908 Usability and Adds New Drug Targets
New mission mode provides simpler and more intuitive sampling of hazardous vapors 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces new capabilities for its handheld MX908 mass spectrometry device for trace chemical identification. These enhancements include an updated mission mode for hazardous vapor sampling and the addition of five priority drug targets, providing first responders with intelligence at the point of need for an informed, confident response. The MX908 mission modes, which include Drug Hunter, Explosives Hunter, and CW (chemical warfare) Hunter, have matured into the most powerful and complete capabilities in the device, offering broader coverage and higher confidence in results. The device’s Hazard Survey mode originally provided users with a broad, but less detailed analysis, and is now replaced with TIC (toxic industrial chemical) Hunter as a dedicated mission mode for focused hazardous vapor detection. |
| 2026-01-20 |
908 Devices Announces Strong Preliminary Financial Results for Fourth Quarter and Full Year 2025
Preliminary full year 2025 revenue of approximately $56 million, representing ~17% growth year-over-year Achieved positive Adjusted EBITDA goal in the fourth quarter 908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today announced preliminary unaudited financial results for the quarter and full year ended December 31, 2025. Preliminary unaudited revenue for the fourth quarter of 2025 is approximately $17.2 million, compared to $14.3 million in the fourth quarter of 2024, reflecting reported growth of approximately 20%. Fourth quarter strength was driven by continued overperformance within the U.S. state and local channel, ramping adoption of VipIR internationally, and sales to federal and defense customers. Preliminary unaudited revenue for the year ended December 31, 2025 is expected to be approximately $56.0 million, compared to audited revenue of $47.7 |